PCSK9 Inhibitors: The New Frontier in Cholesterol Management
Preventive Cardiology PCSK9 Inhibitors: Evolocumab and Inclisiran How PCSK9 inhibitors lower LDL cholesterol by about 50–60% — the mechanism, trial evidence, safety, and access in Australia. Dr Reza Moazzeni, MD FRACP·Consultant Cardiologist·Published 20 Aug 2023·Updated Jun 2026 PCSK9 (proprotein convertase… Read More »PCSK9 Inhibitors: The New Frontier in Cholesterol Management






